131 related articles for article (PubMed ID: 33715419)
1.
Vink G; Nebel JC; Wren SP
Future Med Chem; 2021 Apr; 13(8):691-700. PubMed ID: 33715419
[No Abstract] [Full Text] [Related]
2. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
3. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
Choi YJ; Shin D; Lee JY
Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel potent GPR40 full agonist.
Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for GPR40 allosteric agonism and incretin stimulation.
Ho JD; Chau B; Rodgers L; Lu F; Wilbur KL; Otto KA; Chen Y; Song M; Riley JP; Yang HC; Reynolds NA; Kahl SD; Lewis AP; Groshong C; Madsen RE; Conners K; Lineswala JP; Gheyi T; Saflor MD; Lee MR; Benach J; Baker KA; Montrose-Rafizadeh C; Genin MJ; Miller AR; Hamdouchi C
Nat Commun; 2018 Apr; 9(1):1645. PubMed ID: 29695780
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
7. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
Mohammad S
Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
[TBL] [Abstract][Full Text] [Related]
8. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
Araki T; Hirayama M; Hiroi S; Kaku K
Diabetes Obes Metab; 2012 Mar; 14(3):271-8. PubMed ID: 22051148
[TBL] [Abstract][Full Text] [Related]
9. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
Burant CF
Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
[TBL] [Abstract][Full Text] [Related]
10. Combiphore (Structure and Ligand Based Pharmacophore) - Approach for the Design of GPR40 Modulators in the Management of Diabetes.
Gajjar KA; Gajjar AK
Curr Drug Discov Technol; 2020; 17(2):233-247. PubMed ID: 30306872
[TBL] [Abstract][Full Text] [Related]
11. Molecule of the Month. TAK-875.
Drug News Perspect; 2010 Dec; 23(10):667. PubMed ID: 21180652
[No Abstract] [Full Text] [Related]
12. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875.
Srivastava A; Yano J; Hirozane Y; Kefala G; Gruswitz F; Snell G; Lane W; Ivetac A; Aertgeerts K; Nguyen J; Jennings A; Okada K
Nature; 2014 Sep; 513(7516):124-7. PubMed ID: 25043059
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
[TBL] [Abstract][Full Text] [Related]
14. GPR40: a therapeutic target for mediating insulin secretion (review).
Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules.
Briscoe CP; Peat AJ; McKeown SC; Corbett DF; Goetz AS; Littleton TR; McCoy DC; Kenakin TP; Andrews JL; Ammala C; Fornwald JA; Ignar DM; Jenkinson S
Br J Pharmacol; 2006 Jul; 148(5):619-28. PubMed ID: 16702987
[TBL] [Abstract][Full Text] [Related]
16. Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists.
Liu C; Li Z; Shi W; Li H; Wang N; Dai Y; Liao C; Huang W; Qian H
Chem Biol Drug Des; 2018 Aug; 92(2):1547-1554. PubMed ID: 29777569
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
[TBL] [Abstract][Full Text] [Related]
18. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the Binding Interaction of Fatty Acids with Human G Protein-Coupled Receptor 40 Using a Site-Specific Fluorescence Probe by Flow Cytometry.
Ren XM; Cao LY; Zhang J; Qin WP; Yang Y; Wan B; Guo LH
Biochemistry; 2016 Apr; 55(13):1989-96. PubMed ID: 26974599
[TBL] [Abstract][Full Text] [Related]
20. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
Mancini AD; Poitout V
Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
